SBIROpen

Extremity Platform for On-demand Surgical Implantation and Tissue Integration with Osteochondral Neogenesis

Solicitation ID26.BZ
Agency
DOD
DARPA
Deadline
Jun 3, 2026
15 days left
Posted Date
Apr 13, 2026
Classification
SBIR
Phase: Phase II

SBIR Opportunity Analysis

DARPA, within the Department of Defense, is seeking an SBIR Direct to Phase II solution for an on-demand regenerative medicine platform to restore fingers after traumatic injury and improve military readiness. The work focuses on anatomically precise scaffolds and delivery of bioactive proteins and therapeutic factors to regenerate bone, cartilage, ligaments, tendons, and blood vessels for complete digit restoration and functional recovery. The opportunity emphasizes strong preliminary data for protein engineering, tendon and ligament scaffold integration, and 3D printing, with Phase II centered on animal studies, GMP manufacturing, biocompatibility, CMC development, and optional FDA IDE preparation. This is solicitation DPA26BZ01-DV004 under 26.BZ, and applications are due June 3, 2026 at 4:00 PM UTC.

SBIR Documents

1 Files
1776211345348.pdf
PDF69 KBMay 11, 2026
AI Summary
The DPA26BZ01-DV004 project seeks to develop an on-demand regenerative medicine platform for complete finger restoration following trauma, aiming to eliminate traditional joint repair surgeries and enable full functional recovery. This initiative addresses the high incidence of post-traumatic osteoarthritis (PTOA) in military personnel, which significantly impacts readiness and long-term health. The project proposes a revolutionary approach to biological finger regeneration, focusing on developing anatomically precise scaffolds and delivering bioactive proteins and therapeutic factors to promote the growth of bone, cartilage, ligaments, tendons, and blood vessels. The goal is to restore native tissue architecture and function, allowing service members to return to unrestricted duty. The project is soliciting Direct to Phase II (DP2) proposals, requiring strong preliminary data demonstrating feasibility in protein engineering, tendon/ligament scaffold integration, and 3D printing. Phase II objectives include completing animal studies, establishing GMP manufacturing, and preparing for clinical trials. The technology has dual-use applications, offering commercial potential for treating traumatic joint injuries and congenital joint disorders in civilians, and military benefits in restoring combat readiness, reducing healthcare costs, and improving veteran quality of life.

Related SBIR/STTR Opportunities

Opportunity Snapshot

Source SystemOfficial Link
Program Type
SBIR - Phase II
Agency
DOD / DARPA

Key Dates

Release DateApr 13, 2026
Open DateMay 6, 2026
Application DueJun 3, 2026
Close DateJun 3, 2026